Ionis Pharmaceuticals, Inc. Forecast, price target & analysts
Ionis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Ionis Pharmaceuticals, Inc. Classifications & Recommendation:
Ionis Pharmaceuticals, Inc. Price Target
| Target Price | $58.23 |
| Price | $31.35 |
| Potential |
85.73%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $58.23.
This is
85.73%
register free of charge
$78.00
148.80%
register free of charge
$37.00
18.02%
register free of charge
|
|
| A rating was issued by 25 analysts: 17 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
85.73%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 705.14 | 657.72 |
| 10.48% | 6.72% | |
| EBITDA Margin | -64.26% | -90.79% |
| 52.80% | 41.30% | |
| Net Margin | -68.08% | -92.92% |
| 32.65% | 36.49% |
21 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.04 | -3.87 |
| 18.75% | 27.30% | |
| P/E | negative | |
| EV/Sales | 7.05 |
18 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Ionis Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BMO Capital | Locked ➜ Locked | Locked | Feb 20 2025 |
| Citigroup | Locked ➜ Locked | Locked | Feb 20 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Feb 20 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 20 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Jan 15 2025 |
| Needham | Locked ➜ Locked | Locked | Dec 20 2024 |
| Piper Sandler | Locked ➜ Locked | Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BMO Capital: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
